Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study

In France, squamous cell carcinomas of the head and neck (SCCHN) are the 5th most common cancer. 60% of patients present with locally advanced tumors (stage III/IV), characterized by a poor prognosis (5-year survival not exceeding 60%). The standard treatment consists of either surgical removal followed by adjuvant radiochemotherapy or exclusive radiochemotherapy. In case of locoregional recurrence (about 40% of patients), salvage surgery can be proposed, allowing prolonged survival for less than one third of eligible patients. However, more than half of locoregional recurrences are unresecta

Trial Details

NCT ID

NCT05738187

Phase

NA

Sponsor

University Hospital, Strasbourg, France

Status

RECRUITING

Cancer Type

Salivary Gland Head and Neck Cancer

Interventions

• local cryotherapy treatment

Locations (sample)

• Strasbourg, France|48.58392,7.74553

Key Eligibility Criteria

• Malignant head/neck tumor
• Unresectable locoregional recurrence in a previously irradiated area
• Contraindication to re-irradiation
• Age \> 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Salivary Gland Head and Neck Cancer Trials on Trialify →